Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Investors Cool On Seagen As Merck & Co Merger Hopes Fade
Seagen Suggests Focus On Own M&A
Sep 16 2022
•
By
Andrew McConaghie
Merck has said to have cooled off because of Seagen's asking price - but a deal might still be struck. • Source: Shutterstock
More from Deals
More from Business